Novartis AG (FRA:NOT) Institutional Ownership: 41.41% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NOT Novartis AG FRA:NOT
81 GF Score
Price €135.38
GF Value €113.05
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Institutional Ownership?

Novartis AG FRA:NOT +1.12% 81 Institutional Ownership is 41.41% as of Jul. 14, 2026. GuruFocus rates FRA:NOT with a GF Score™ of 81/100 and a GF Value™ of €113.05 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Novartis AG's institutional ownership is 41.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Novartis AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Novartis AG's Float Percentage Of Total Shares Outstanding is 99.92%.

Novartis AG Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Novartis AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Institutional Ownership Chart

Novartis AG Historical Data

The historical data trend for Novartis AG can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 39.10 39.29 39.21 40.51 40.53 41.37 41.25 41.50 41.42 41.41
FRA:NOT
81GF Score
Novartis AG FRA:NOT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 41.41% mean?
Novartis AG (FRA:NOT) has a Institutional Ownership of 41.41% as of Jul. 14, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Novartis AG and its competitors.
Is Novartis AG's Institutional Ownership too high?
Novartis AG's current Institutional Ownership is 41.41%. Overall, Novartis AG has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Institutional Ownership compare to LLY and JNJ?
Novartis AG's Institutional Ownership of 41.41% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Novartis AG and its competitors. Novartis AG's current Institutional Ownership is 41.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT) is currently considered Modestly Overvalued. The stock's GF Value™ is €113.05, compared to a current price of €135.38 — trading 19.8% above its estimated fair value. The current Institutional Ownership is 41.41%. Novartis AG's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Novartis AG (FRA:NOT), the current Institutional Ownership is 41.41% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €135.38 is trading 19.8% above its estimated GF Value™ of €113.05. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT:

  • Institutional Ownership: 41.41%
  • GF Value™: €113.05 vs. price of €135.38 (19.8% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the FRA:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
81GF Score

Get the complete analysis for FRA:NOT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€135.38
Price
€113.05
GF Value